An open-label extension study for patients with severe chronic low back pain or severe chronic pain due to knee osteoarthritis who have completed any of the previous phase IIIb trials with tapentadol hydrochloride, KF5503/42, KF5503/44 or KF5503/45.
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2012
At a glance
- Drugs Tapentadol (Primary) ; Tapentadol (Primary)
- Indications Back pain; Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- 29 Jun 2012 Planned end date (May 2012) added as reported by European Clinical Trials Database record.
- 21 Jun 2011 New trial record